Xencor Reports the First Individual Dosing with XmAb942 in P-I/II Trial to Treat Inflammatory Bowel Disease
Shots:
- Xencor has dosed the first individual with XmAb942 under its P-I/II clinical evaluation for treating inflammatory bowel disease
- The P-I/II trial will assess XmAb942 in three parts, with part A & B in the P-I recruiting healthy subjects for single-ascending dose (SAD) arm and repeat-doses, respectively and part C in P-II enrolling patients with ulcerative colitis to receive dosing levels determined in parts A & B. P-I dose-escalation began in late 2024, with initial data expected in H1’25
- XmAb942 is a high-potency, long-acting anti-TL1A Ab being developed for IBD, incl. UC & CD. It prevents the binding of death receptor 3 (DR3) receptor & tumor necrosis factor (TNF)-like cytokine 1A (TL1A) for reduced activity
Ref: Xencor | Image: Xencor
Related News:- Cytoki Pharma Reports the First Patient Dosing with CK-0045 in the P-II Trial for Treating Obesity and Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
